leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...163164165166167168169170171172173...235236»
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen
    The Use of Early Continuous Venovenous Haemofiltration and Glucarpidase Therapy in the Management of Methotrexate Toxicity () -  Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5849;    
    The patient did not develop any haemorrhagic or infective complications of myelosuppression and continued to improve until his successful discharge after 29 days. This case demonstrates that combination therapy of early CVVH with glucarpidase therapy in conjunction with high dose leucovorin can be associated with promising outcomes in terms of therapy of MTX toxicity.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Biomarker, Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC (clinicaltrials.gov) -  Oct 22, 2019   
    P2/3,  N=200, Not yet recruiting, 
    This case demonstrates that combination therapy of early CVVH with glucarpidase therapy in conjunction with high dose leucovorin can be associated with promising outcomes in terms of therapy of MTX toxicity. Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
  • ||||||||||  leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
    Biomarker, Journal:  Pancreatic Neoplasms and Autophagy. (Pubmed Central) -  Oct 19, 2019   
    To this end, novel therapeutic avenues are sought for pancreatic cancer. This mini-review summarizes the state-of-the-art of pancreatic cancer treatment, and possible role of autophagy in therapeutics against pancreatic cancer.
  • ||||||||||  leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
    Clinical, Review, Journal:  Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? (Pubmed Central) -  Oct 17, 2019   
    Later, preliminary results of PRODIGE 24 trial presented at the 2018 ASCO meeting showed a superiority of a combination chemotherapy regimen with fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) when compared to gemcitabine alone, both in terms of median disease-free survival (21.6 vs. 12.8 months, p < 0.0001) and OS (54.4 vs. 35 months, p = 0.003)...Overall, the management of localized pancreatic adenocarcinoma is evolving. In this review, we summarize the current status and the most up-to-date developments in adjuvant treatment.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date:  PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer (clinicaltrials.gov) -  Oct 15, 2019   
    P=N/A,  N=48, Recruiting, 
    In this review, we summarize the current status and the most up-to-date developments in adjuvant treatment. Completed --> Recruiting | N=30 --> 48 | Trial completion date: Apr 2017 --> Dec 2019 | Trial primary completion date: Apr 2017 --> Dec 2019
  • ||||||||||  Opdivo (nivolumab) / BMS
    Phase classification:  CA209-8TT: Pan Tumor Rollover Study (clinicaltrials.gov) -  Oct 15, 2019   
    P2,  N=1200, Recruiting, 
    Completed --> Recruiting | N=30 --> 48 | Trial completion date: Apr 2017 --> Dec 2019 | Trial primary completion date: Apr 2017 --> Dec 2019 Phase classification: P4 --> P2
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen
    DAMPAned Methotrexate Levels: A Case Report of Acute Methotrexate Toxicity (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1507;    
    He previously received two cycles of R-CHOP chemotherapy...Despite extracellular volume expansion, urinary alkalinization, and leucovorin rescue, he developed severe acute kidney injury (SCr 374 µmol/L) and subsequently went into status epilepticus...Discussion Glucarpidase is an effective option for non-renal elimination of toxic methotrexate concentrations in patients with nephrotoxicity. Awareness of how to access the drug, protocolization of monitoring including specific laboratory requirements, and knowledge of alternative treatments is necessary for centres where HDMTX therapy is used.
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Enrollment closed, Enrollment change, Metastases:  Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) -  Oct 14, 2019   
    P3,  N=27, Active, not recruiting, 
    Awareness of how to access the drug, protocolization of monitoring including specific laboratory requirements, and knowledge of alternative treatments is necessary for centres where HDMTX therapy is used. Recruiting --> Active, not recruiting | N=172 --> 27
  • ||||||||||  leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
    Review, Journal:  Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. (Pubmed Central) -  Oct 12, 2019   
    Nevertheless, gemcitabine remains the standard first-line option for advanced-stage pancreatic cancer patients and, as resistance to the drug has attracted an increasing scientific interest, we deliberate on the main intracellular processes and proteins vital in acquired chemoresistance to gemcitabine. Lastly, our review examines various microenvironmental factors capable of instigating PDAC to develop resistance to chemotherapeutic drugs.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Trial completion, Enrollment change, Trial completion date, Combination therapy, Metastases:  Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) -  Oct 11, 2019   
    P2,  N=108, Completed, 
    Lastly, our review examines various microenvironmental factors capable of instigating PDAC to develop resistance to chemotherapeutic drugs. Active, not recruiting --> Completed | N=375 --> 108 | Trial completion date: Mar 2019 --> Jul 2019
  • ||||||||||  veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
    Trial suspension, Trial primary completion date, Metastases:  NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) -  Oct 8, 2019   
    P2,  N=348, Suspended, 
    Such integrated technology allows the design of innovative management approaches, ultimately improving patients' experience with chemotherapy, wellbeing, and outcomes. Recruiting --> Suspended | Trial primary completion date: Apr 2019 --> Mar 2020
  • ||||||||||  leucovorin calcium / generics, irinotecan / generics
    Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer : A phase 2 clinical trial. () -  Oct 4, 2019 - Abstract #CRICIMTEATIAACR2019CRI-CIMT-EATI-AACR_193;    
    Objective: To evaluate the margin-negative (R0) resection rate of neoadjuvant FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) and losartan followed by chemoradiotherapy for locally advanced pancreatic cancer...Patients with radiographically resectable tumor after chemotherapy received short-course chemoradiotherapy (5 GyE × 5 with protons) with capecitabine...Among patients who underwent resection, median progression-free survival was 21.3 months (95% CI, 16.6-28.2), and median overall survival was 33.0 months (95% CI, 31.4 to not reached). Conclusion and relevance: Total neoadjuvant therapy with FOLFIRINOX, losartan, and chemoradiotherapy provides downstaging of locally advanced pancreatic ductal adenocarcinoma and is associated with an R0 resection rate of 61%.
  • ||||||||||  BL-8040 / BioLineRx
    Combination of BL-8040, anti PD-1 and chemotherapy significantly reduced pancreatic tumor growth and changed the balance between CD4+/FOXP3+ cells and CD8+ cells in the tumor (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_832;    
    TCT reduced significantly the number CD4+ and CD4+FOXP3+ cells and increased the numbers of activated CD8+, CD69+ cells in the TME. We hypothesize, that the ability of BL-8040 to modulate the TME may allow better activation of immune effector cells, contributing to the effect of chemotherapy and immunotherapy on tumor growth .A Phase IIa, multicenter, open label trial in patients with metastatic pancreatic cancer (the COMBAT study cohort II, (3)) is currently ongoing to assess the effect of the triple combination with BL-8040, +Pembrolizumab and ILF on disease progression.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. (Pubmed Central) -  Oct 2, 2019   
    These results were found independently of the treatment received, and no beneficial effect of cetuximab on DFS or OS was observed in left-sided tumors. Although right-sided tumor location is associated with poor survival in patients with metastatic CC as previously reported, the association with disease recurrence appears to vary for patients with stage III CC and RAS or BRAF mutations vs those with double wild type.
  • ||||||||||  Rituxan (rituximab) / Roche
    Trial completion date, Trial primary completion date:  LeMLAR: Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas (clinicaltrials.gov) -  Oct 1, 2019   
    P1/2,  N=37, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Jun 2019 --> Dec 2019
  • ||||||||||  Rituxan (rituximab) / Roche
    Enrollment change:  LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (clinicaltrials.gov) -  Sep 30, 2019   
    P1,  N=12, Recruiting, 
    Recruiting --> Active, not recruiting | N=100 --> 70 | Trial completion date: May 2021 --> Jan 2020 | Trial primary completion date: Aug 2020 --> Jan 2020 N=24 --> 12
  • ||||||||||  leucovorin calcium / generics, methotrexate / generics
    Standardized supportive therapy documentation improves patient safety when using high-dose methotrexate (R9) -  Sep 30, 2019 - Abstract #DGHO2019DGHO_1556;    
    SOPs including a checklist for the documentationof supportive care prior to HD-MTX and a strict protocol for urine alkalization during HD-MTX therapy are able to significantly improve safety and reduce the rates of adverse effects. Use of these rigorous safety tools is encouraged to prevent unneccessary, life-threatening toxicity in patients undergoing HD-MTX.
  • ||||||||||  leucovorin calcium / generics, methotrexate / generics
    Clinical, Journal:  Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature. (Pubmed Central) -  Sep 30, 2019   
    There is no randomised clinical evidence to support its use in severe cases and theoretical evidence suggests that after prolonged exposure to high MTX levels glucarpidase administration is unable to reverse high intracellular MTX. We recommend that new randomised controlled studies be aimed at early administration of glucarpidase in patients with high MTX levels shortly after administration to prevent direct toxic effects of MTX on kidney function and further uptake into cells.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Review, Journal:  Advancements and challenges in treating advanced gastric cancer in the West. (Pubmed Central) -  Sep 29, 2019   
    Intraperitoneal chemotherapy may also play a role in preventing peritoneal recurrences for patients with high risk lesions. The treatment of patients with advanced gastric cancer in the West continues to advance and improve with a better understanding of optimal treatment sequences and the utilization of personalized treatment regimens.